RTALB RTA LABORATUVARLARI BİYOLOJİK ÜRÜNLER İLAÇ VE MAKİNE SANAYİ TİCARET A.Ş. Stock
RTA Laboratuvarları, biyolojik ürünler, ilaç ve makine sanayisinde faaliyet gösteren bir şirkettir. Kimya ve petrokimya sektöründe yenilikçi çözümler sunmaktadır.
| Period | Revenue | EBITDA | Net Income |
|---|---|---|---|
| 2026 Q2 | 89.6M | -319.7M | -269.3M |
| 2026 Q1 | 82.6M | -304.3M | -298.3M |
| 2025 Q4 | 74.4M | 791.6M | 542.0M |
| 2025 Q3 | 60.0M | 161.6M | 78.6M |
| 2025 Q2 | 53.0M | 141.4M | 104.6M |
| 2025 Q1 | 52.2M | 202.5M | 214.8M |
| 2024 Q4 | 42.1M | 103.6M | 26.0M |
| 2024 Q3 | 47.9M | -36.1M | 87.3M |
| Period | P/E (TTM) | TTM Net Income | E/P Quarterly | E/P Annual (TTM) |
|---|---|---|---|---|
| 2026 Q2 | 32.8 | 53.0M TRY | -0.1552 | 0.0305 |
| 2026 Q1 | 4.1 | 426.9M TRY | -0.1724 | 0.2467 |
| 2025 Q4 | 1.8 | 940.0M TRY | 0.3160 | 0.5480 |
| 2025 Q3 | 4.4 | 424.0M TRY | 0.0422 | 0.2279 |
| 2025 Q2 | 3.3 | 432.8M TRY | 0.0734 | 0.3037 |
| 2025 Q1 | 10.0 | 141.3M TRY | 0.1523 | 0.1002 |
| 2024 Q4 | 27.8 | 52.2M TRY | 0.0179 | 0.0360 |
| 2024 Q3 | — | -222.1M TRY | 0.0560 | -0.1423 |
| Period | Net Margin | Gross Margin | ROE | ROA | Debt/Equity | Rev. Growth (YoY) |
|---|---|---|---|---|---|---|
| 2026 Q2 | -300.6% | 8.5% | — | -32.8% | — | +69.1% |
| 2026 Q1 | -361.3% | 37% | — | -34.2% | — | +58.1% |
| 2025 Q4 | 728.8% | 29.9% | 73.1% | 63.1% | 0.03 | +76.8% |
| 2025 Q3 | 131% | 37.6% | 13.4% | 12.7% | 0.02 | +25.2% |
| 2025 Q2 | 197.4% | 36.7% | 19.7% | 18.8% | 0.02 | +39% |
| 2025 Q1 | 411.3% | 35.7% | 44.8% | 40.6% | 0.07 | +71.3% |
| 2024 Q4 | 61.9% | 26.3% | 6.2% | 5.4% | 0.12 | -5.4% |
| 2024 Q3 | 182.3% | 31.7% | 22.6% | 20% | 0.09 | +148.6% |
| Period | P/B |
|---|---|
| 2026 Q2 | 0.59 |
| 2026 Q1 | 0.58 |
| 2025 Q4 | 0.58 |
| 2025 Q3 | 0.80 |
| 2025 Q2 | 0.67 |
| 2025 Q1 | 0.74 |
| 2024 Q4 | 0.87 |
| 2024 Q3 | 1.01 |
What is the RTALB stock price?
The current price of RTALB is 2.87 TRY. (2026-08-31)
What is the RTALB E/P ratio?
The annual (TTM) E/P ratio of RTALB is 0.0305. Market cap: 1.7B TRY.
What sector is RTALB in?
RTALB (RTA LABORATUVARLARI BİYOLOJİK ÜRÜNLER İLAÇ VE MAKİNE SANAYİ TİCARET A.Ş.) operates in the Kimya ve Petrokimya sector.
What is the RTALB P/B ratio?
The P/B (Price-to-Book) ratio of RTALB is 0.59.
RTALB Stock Analysis — Borsa Istanbul
This page provides a comprehensive analysis of RTALB (RTA LABORATUVARLARI BİYOLOJİK ÜRÜNLER İLAÇ VE MAKİNE SANAYİ TİCARET A.Ş.), a company listed on Borsa Istanbul in the Kimya ve Petrokimya sector. The current share price, daily percentage change, and trading volume are updated at the end of each trading session using official BIST data.
Momentum and Technical Indicators
Short-term and medium-term momentum indicators for RTALB are calculated using 21-day and 63-day return windows. The 21-day Sortino ratio measures risk-adjusted performance by penalizing only downside volatility, providing a cleaner signal than standard deviation-based metrics. Annualized volatility and 252-day (one-year) momentum are also displayed to help investors assess both trend strength and risk characteristics of RTALB relative to its sector peers.
Fundamental Metrics
Key valuation ratios include the Earnings-to-Price (E/P) ratio calculated on both quarterly and trailing twelve-month (TTM) bases, the Price-to-Book (P/B) ratio derived from the most recent balance sheet equity, and market capitalization. Financial health indicators such as ROE (Return on Equity), ROA (Return on Assets), net profit margin, gross margin, and debt-to-equity ratio are sourced from the latest disclosed quarterly financial statements filed with KAP (Public Disclosure Platform).
Sector Comparison
RTALB is compared against other stocks in the Kimya ve Petrokimya sector across momentum, valuation, and profitability dimensions. The sector comparison table ranks RTALB against its peers using percentile scores, making it easy to identify whether the stock is relatively cheap (high E/P), growing faster (high momentum), or more profitable (high ROE) compared to the sector median. All data is refreshed daily and financial ratios are updated each quarter after earnings disclosures.